Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, Ingrosso G, D'Angelillo RM, Alitto AR, Augugliaro M, Triggiani L, Parisi S, Facchini G, Banini M, Simontacchi G, Desideri I, Meattini I, Valicenti RK, Livi L; ARTO Working Group members. Francolini G, et al. Among authors: alitto ar. J Clin Oncol. 2023 Dec 20;41(36):5561-5568. doi: 10.1200/JCO.23.00985. Epub 2023 Sep 21. J Clin Oncol. 2023. PMID: 37733977 Clinical Trial.
Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
Boldrini L, Romano A, Chiloiro G, Corradini S, De Luca V, Verusio V, D'Aviero A, Castelluccia A, Alitto AR, Catucci F, Grimaldi G, Trapp C, Hörner-Rieber J, Marchesano D, Frascino V, Mattiucci GC, Valentini V, Gentile P, Gambacorta MA. Boldrini L, et al. Among authors: alitto ar. Radiat Oncol. 2023 May 22;18(1):84. doi: 10.1186/s13014-023-02271-y. Radiat Oncol. 2023. PMID: 37218005 Free PMC article.
Multiparametric imaging guided HDR interventional radiotherapy (brachytherapy) boost in localized prostate cancer: a multidisciplinary experience.
Tagliaferri L, Alemanno G, Fionda B, Alitto AR, Frascino V, Cellini F, Lancellotta V, Placidi E, Morganti AG, Kovács G, Giordano A, Manfredi R, Valentini V. Tagliaferri L, et al. Among authors: alitto ar. Eur Rev Med Pharmacol Sci. 2023 May;27(9):4175-4184. doi: 10.26355/eurrev_202305_32327. Eur Rev Med Pharmacol Sci. 2023. PMID: 37203844 Free article.
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. Among authors: alitto ar. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
Radiation therapy for prostate cancer: What's the best in 2021.
Cellini F, Tagliaferri L, Frascino V, Alitto AR, Fionda B, Boldrini L, Romano A, Casà C, Catucci F, Mattiucci GC, Valentini V. Cellini F, et al. Among authors: alitto ar. Urologia. 2022 Feb;89(1):5-15. doi: 10.1177/03915603211042335. Epub 2021 Sep 8. Urologia. 2022. PMID: 34496707
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Munoz F, Fiorica F, Caravatta L, Rosa C, Ferella L, Boldrini L, Fionda B, Alitto AR, Nardangeli A, Dionisi F, Arcangeli S, Di Marzo A, Pontoriero A, Donato V, Massaccesi M. Munoz F, et al. Among authors: alitto ar. Cancer Treat Rev. 2021 Apr;95:102176. doi: 10.1016/j.ctrv.2021.102176. Epub 2021 Mar 8. Cancer Treat Rev. 2021. PMID: 33743409
Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study.
Palumbo C, Bruni A, Antonelli A, Artibani W, Bassi P, Bertoni F, Borghetti P, Bracarda S, Cicchetti A, Corvò R, Gacci M, Ingrosso G, Magrini SM, Maruzzo M, Mirone V, Montironi R, Muto G, Noale M, Porreca A, Russi E, Triggiani L, Tubaro A, Valdagni R, Maggi S, Conti GN; Pros-IT CNR Study Group. Palumbo C, et al. Minerva Urol Nephrol. 2022 Feb;74(1):11-20. doi: 10.23736/S2724-6051.20.04032-1. Epub 2021 Jan 13. Minerva Urol Nephrol. 2022. PMID: 33439570 Free article.
The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.
Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, Bracarda S, Briganti A, Carmignani G, Carmignani L, Conti GN, Corvò R, DE Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, Crepaldi G; Pros-IT CNR Study Group. Gacci M, et al. Minerva Urol Nephrol. 2022 Feb;74(1):38-48. doi: 10.23736/S2724-6051.20.03925-9. Epub 2020 Nov 17. Minerva Urol Nephrol. 2022. PMID: 33200896 Free article.
31 results